Melanoma linked with CLL, close monitoring recommended

August 9, 2018, University of Rochester Medical Center
Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0

While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery—these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer.

Although a higher risk of melanoma had been known, a full analysis of detection rates and treatments among CLL patients has never been reported before, said Clive Zent, M.D., who led the study. It was published by the journal Leukemia Research.

As a result of this new data, Zent, an international expert in CLL, recommends that all clinical teams who care for CLL patients should actively monitor for melanoma as a part of routine care. The goal is to catch the skin cancer early and manage it with the newest targeted therapies.

"We do not for sure know why CLL patients are more susceptible to melanoma, but the most likely cause is a suppressed immune system," said Zent, a professor of Hematology/Oncology and Medicine at the University of Rochester Medical Cancer and Wilmot. "Normally, in people with healthy immune systems, malignant skin cells might be detected and destroyed before they become a problem. But in CLL , failure of this control system increases the rate at which cancer cells can grow into tumors, and also the likelihood that they will become invasive or spread to distant sites."

Study results showed that 22 melanomas were diagnosed among 470 people in the cohort, a rate that's more than 600 percent higher than what would be expected in a similar group of age- and gender-matched people from the general population. Of the 22 diagnoses, 15 (or 68 percent) were detected through monitoring in the UR Medicine dermatology clinic associated with Wilmot, and two cases (9 percent) were found by CLL specialists. Eighty eight percent of the cases involved earlier-stage disease with a better prognosis, the study said.

Researchers also noted a bright spot: one CLL patient, a 75-year-old woman, who developed advanced , was treated with a targeted -immunotherapy drug, pembrolizumab (Keytruda), and went into remission for more than two years. She had been taking another targeted therapy, ibrutinib, for the leukemia. Zent believes this is the first published report to offer evidence that the ibrutinib/pembrolizumab combination was effective.

CLL is the most common type of leukemia in the U.S., with about 140,000 people living with the disease. Immune dysfunction is a major complication. Zent said the

Wilmot research supports the need for larger studies to seek solutions for the CLL/ risk.

The Cadregari Endowment Fund at the Wilmot Cancer Institute supported the investigation. First author is William J. Archibald, a former UR School of Medicine and

Dentistry student who has since graduated and performed much of the work on the study while in Rochester. Zent is editor-in-chief of the journal that published the paper, but he was blinded to the peer-review process, which was overseen by another editor at the journal.

Explore further: Research is changing the game for melanoma treatment

More information: William J. Archibald et al, Management of melanoma in patients with chronic lymphocytic leukemia, Leukemia Research (2018). DOI: 10.1016/j.leukres.2018.07.003

Related Stories

Research is changing the game for melanoma treatment

February 1, 2018
Wilmot Cancer Institute patients with advanced melanoma (stage III) now have more options for treatment, thanks to research co-authored by a University of Rochester Medical Center surgical oncologist and published in The ...

Skin cancer risk higher in military personnel

July 8, 2018
(HealthDay)—There is an increased risk for skin cancer among U.S. active duty service members and veterans, according to a review published in the June issue of the Journal of the American Academy of Dermatology.

Obesity linked to improved survival in male melanoma patients

March 26, 2018
Obese patients with metastatic melanoma live significantly longer than those with normal body mass indexes (BMI), according to a new study published in Lancet Oncology. The surprising association was mainly seen in male patients ...

Cancer drug keytruda a new weapon against advanced lung tumors

June 4, 2018
(HealthDay)—A cancer drug that boosts the immune system outperforms chemotherapy in fighting advanced lung cancer, a new trial shows.

PAs may have lower diagnostic accuracy for melanoma

April 20, 2018
(HealthDay)—Physician assistants (PAs) perform more skin biopsies per case of skin cancer diagnosed and diagnose fewer melanomas in situ than dermatologists, according to a study published online April 18 in JAMA Dermatology.

Clinical trial results show new drug is better for CLL patients

December 6, 2015
Older adults with chronic lymphocytic leukemia may have an alternative to toxic chemotherapy as their first treatment, according to a national study to be reported online Dec. 6, 2015, in the New England Journal of Medicine ...

Recommended for you

Student develops microfluidics device to help scientists identify early genetic markers of cancer

October 16, 2018
As anyone who has played "Where's Waldo" knows, searching for a single item in a landscape filled with a mélange of characters and objects can be a challenge. Chrissy O'Keefe, a Ph.D. student in the Department of Biomedical ...

A bad influence—the interplay between tumor cells and immune cells

October 16, 2018
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ...

Technique to 'listen' to a patient's brain during tumour surgery

October 16, 2018
Surgeons could soon eavesdrop on a patient's brain activity during surgery to remove their brain tumour, helping improve the accuracy of the operation and reduce the risk of impairing brain function.

Researchers elucidate roles of TP63 and SOX2 in squamous cell cancer progression

October 16, 2018
Squamous cell carcinomas (SCCs) are aggressive malignancies arising from the squamous epithelium of various organs, such as the esophagus, head and neck, lungs, and skin. Previous studies have demonstrated that two master ...

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Delving where few others have gone, leukemia researchers open new path

October 15, 2018
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.